Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 2, 2023
Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET...
-
Oct 26, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...
-
Oct 6, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 2, 2023, the independent...
-
Sep 12, 2023
Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D. Academics and industry professionals will gather virtually on September 22, 2023 LEXINGTON, Mass., Sept. 12, 2023...
-
Sep 6, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...
-
Aug 3, 2023
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong...
-
Jul 27, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancies,...
-
Jul 6, 2023
Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment...
-
Jul 6, 2023
Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, today...
-
May 5, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Board of Directors of Curis approved...